Effects of adenosine triphosphate, thiamine pyrophosphate, melatonin, and liv-52 on subacute pyrazinamide proliferation hepatotoxicity in rats

BMC Pharmacol Toxicol. 2025 Mar 24;26(1):67. doi: 10.1186/s40360-025-00901-7.

Abstract

Background: Hepatotoxicity of pyrazinamide, an antituberculosis drug, limits its therapeutic use and oxidative stress has been implicated in this toxicity. This study investigated the protective effects of adenosine triphosphate (ATP), thiamine pyrophosphate (TPP), melatonin, and Liv-52, which have previously been shown antioxidant activities, on pyrazinamide-induced hepatotoxicity.

Methods: 36 albino Wistar male rats were divided into randomized six groups; healthy (HG), pyrazinamide (PZG), ATP + pyrazinamide (APZG), TPP + pyrazinamide (TPZG), melatonin + pyrazinamide (MPZG) and Liv-52 + pyrazinamide (LPZG) groups. ATP 4 mg/kg and TPP 25 mg/kg were administered intraperitoneally (IP). Melatonin 10 mg/kg and Liv-52 20 mg/kg were given orally. One hour after administration of ATP, TPP, melatonin, and Liv-52, 250 mg/kg pyrazinamide was applied orally to all rats except HG group. The treatment was repeated (1 × 1) for 4 weeks. Then, blood samples were taken for determination of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities. Immediately after, the rats were euthanized with thiopental sodium (50 mg/kg, IP), and the livers were removed. The tissues were analyzed for malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), and catalase (CAT) also hydropic degeneration, necrosis, and apoptosis (caspase 3) were examined.One-Way ANOVA was used in biochemical analyses and Tukey test was used as post-hoc. For histopathological and immunohistochemical analysis, the Kruskal-Wallis test was used and Dunn's test as a post-hoc.

Results: Pyrazinamide increased MDA land decreased tGSH, SOD, and CAT levels in liver tissues (p < 0.001). It also increased serum ALT and AST activities and caused severe hydropic degeneration and necrosis in liver tissue (p < 0.001). ATP, TPP, melatonin, and Liv-52 significantly prevented the biochemical and histopathological changes induced by pyrazinamide (p < 0.05). On the other hand, Liv-52 was more successful than other potential protectors in protecting liver tissue from pyrazinamide damage (p < 0.05).

Conclusions: ATP, TPP, melatonin, and Liv-52 can be used to protect liver tissue from pyrazinamide-induced hepatotoxicity in rats.

Keywords: ATP; Antioxidant effect; Liv-52; Liver toxicity; Pyrazinamide; Thiamine pyrophosphate.

MeSH terms

  • Adenosine Triphosphate* / pharmacology
  • Adenosine Triphosphate* / therapeutic use
  • Alanine Transaminase / blood
  • Animals
  • Antioxidants* / pharmacology
  • Antioxidants* / therapeutic use
  • Antitubercular Agents* / toxicity
  • Aspartate Aminotransferases / blood
  • Cell Proliferation / drug effects
  • Chemical and Drug Induced Liver Injury* / drug therapy
  • Chemical and Drug Induced Liver Injury* / metabolism
  • Chemical and Drug Induced Liver Injury* / pathology
  • Liver / drug effects
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Melatonin* / pharmacology
  • Melatonin* / therapeutic use
  • Pyrazinamide* / toxicity
  • Rats
  • Rats, Wistar
  • Thiamine Pyrophosphate* / pharmacology
  • Thiamine Pyrophosphate* / therapeutic use

Substances

  • Pyrazinamide
  • Adenosine Triphosphate
  • Melatonin
  • Thiamine Pyrophosphate
  • Antitubercular Agents
  • Antioxidants
  • Alanine Transaminase
  • Aspartate Aminotransferases